Mechanism-based inactivation of lung-selective cytochrome P450 CYP2F enzymes

Drug Metabolism and Disposition

Volumn 36, Issue 1, 2008, Pages 155-162

  Kartha, Jaya S ^a   Yost, Garold S ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHOXYCOUMARIN DEETHYLASE; CARBON MONOXIDE; CYTOCHROME P450; CYTOCHROME P450 CYP2F; GLUTATHIONE; SKATOLE; UNCLASSIFIED DRUG;

ARTICLE; DEHYDROGENATION; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INACTIVATION; NONHUMAN; PARTITION COEFFICIENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; REACTION ANALYSIS;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GOATS; HUMANS; LUNG; MICROSOMES; SKATOLE; TIME FACTORS;

CAPRA HIRCUS;

EID: 37549055081     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.017897     Document Type: Article

References (42)

1. Barnes HJ, Arlotto MP, and Waterman MR (1991) Expression and enzymatic activity of recombinant cytochrome P450 17α-hydroxylase in Escherichia coli. Proc Natl Acad Sci U S A 88:5597-5601.
2. Fan PW, Zhang F, and Bolton JL (2000) 4-Hydroxylated metabolites of the antiestrogens tamoxifen and toremifene are metabolized to unusually stable quinone methides. Chem Res Toxicol 13:45-52.
3. Forkert PG, Lee RP, and Reid K (2001) Involvement of CYP2E1 and carboxylesterase enzymes in vinyl carbamate metabolism in human lung microsomes. Drug Metab Dispos 29:258-263.
4. Gillam EM (1998) Human cytochrome P450 enzymes expressed in bacteria: reagents to probe molecular interactions in toxicology. Clin Exp Pharmacol Physiol 25:877-886.
5. Greenlee WF and Poland A (1978) An improved assay of 7-ethoxycoumarin O-deethylase activity: induction of hepatic enzyme activity in C57BL/6J and DBA/2J mice by phenobarbital, 3-methylcholanthrene and 2,3,7,8- tetrachlorodibenzo-p-dioxin. J Pharmacol Exp Ther 205:596-605.
6. Guengerich FP, Martin MV, Guo Z, and Chun YJ (1996) Purification of functional recombinant P450s from bacteria. Methods Enzymol 272:35-44.
7. He MM, Smith AS, Oslob JD, Flanagan WM, Braisted AC, Whitty A, Cancilla MT, Wang J, Lugovskoy AA, Yoburn JC, et al. (2005) Small-molecule inhibition of TNF-α. Science 310:1022-1025.
8. Hollenberg PF (2002) Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. Drug Metab Rev 34:17-35.
9. Huijzer JC, Adams JD Jr, and Yost GS (1987) Decreased pneumotoxicity of deuterated 3-methylindole: bioactivation requires methyl C-H bond breakage. Toxicol Appl Pharmacol 90:60-68.
10. Kassahun K, Skordos K, McIntosh I, Slaughter D, Doss GA, Baillie TA, and Yost GS (2005) Zafirlukast metabolism by cytochrome P450 3A4 produces an electrophilic α, β-unsaturated iminium species that results in the selective mechanism-based inactivation of the enzyme. Chem Res Toxicol 18:1427-1437.
11. Kent UM, Juschyshyn MI, and Hollenberg PF (2001) Mechanism-based inactivators as probes of cytochrome P450 structure and function. Curr Drug Metab 2:215-243.
12. Kitz R and Wilson IB (1962) Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem 237:3245-3249.
13. Lanza DL, Code E, Crespi CL, Gonzalez FJ, and Yost GS (1999) Specific dehydrogenation of 3-methylindole and epoxidation of naphthalene by recombinant human CYP2F1 expressed in lymphoblastoid cells. Drug Metab Dispos 27:798-803.
14. Lanza DL and Yost GS (2001) Selective dehydrogenation/oxygenation of 3-methylindole by cytochrome p450 enzymes. Drug Metab Dispos 29:950-953.
15. 2-terminal segment retains catalytic activity and is membrane-bound when expressed in Escherichia coli. J Biol Chem 266:7321-7324.
16. 5-dependent: metabolic activation of the ethynyl moiety leads to the formation of glutathione conjugates, a heme adduct, and covalent binding to the apoprotein. J Pharmacol Exp Ther 321:276-287.
17. Lin HL, Kent UM, and Hollenberg PF (2005) The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5. J Pharmacol Exp Ther 313:154-164.
18. Lucas D, Berthou F, Girre C, Poitrenaud F, and Menez JF (1993) High-performance liquid chromatographic determination of chlorzoxazone and 6-hydroxychlorzoxazone in serum: a tool for indirect evaluation of cytochrome P4502E1 activity in humans. J Chromatogr 622:79-86.
19. Nakajima T, Elovaara E, Gonzalez FJ, Gelboin HV, Raunio H, Pelkonen O, Vainio H, and Aoyama T (1994) Styrene metabolism by cDNA-expressed human hepatic and pulmonary cytochromes P450. Chem Res Toxicol 7:891-896.
20. Nocerini MR, Carlson JR, and Yost GS (1985a) Glutathione adduct formation with microsomally activated metabolites of the pulmonary alkylating and cytotoxic agent, 3-methylindole. Toxicol Appl Pharmacol 81:75-84.
21. Nocerini MR, Yost GS, Carlson JR, Liberato DJ, and Breeze RG (1985b) Structure of the glutathione adduct of activated 3-methylindole indicates that an imine methide is the electrophilic intermediate. Drug Metab Dispos 13:690-694.
22. Omura T and Sato R (1964a) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
23. Omura T and Sato R (1964b) The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties. J Biol Chem 239:2379-2385.
24. Osawa Y and Pohl LR (1989) Covalent bonding of the prosthetic heme to protein: a potential mechanism for the suicide inactivation or activation of hemoproteins. Chem Res Toxicol 2:131-141.
25. Powley MW and Carlson GP (2001) Cytochrome P450 isozymes involved in the metabolism of phenol, a benzene metabolite. Toxicol Lett 125:117-123.
26. Racha JK, Rettie AE, and Kunze KL (1998) Mechanism-based inactivation of human cytochrome P450 1A2 by furafylline: detection of a 1:1 adduct to protein and evidence for the formation of a novel imidazomethide intermediate. Biochemistry 37:7407-7419.
27. Regal KA, Laws GM, Yuan C, Yost GS, and Skiles GL (2001) Detection and characterization of DNA adducts of 3-methylindole. Chem Res Toxicol 14:1014-1024.
28. 4-VPA, a toxic metabolite of valproic acid. Science 235:890-893.
29. Scott EE, Spatzenegger M, and Halpert JR (2001) A truncation of 2B subfamily cytochromes P450 yields increased expression levels, increased solubility, and decreased aggregation while retaining function. Arch Biochem Biophys 395:57-68.
30. Sheets PL, Yost GS, and Carlson GP (2004) Benzene metabolism in human lung cell lines BEAS-2B and A549 and cells overexpressing CYP2F1. J Biochem Mol Toxicol 18:92-99.
31. Silverman RB (1995) Mechanism-based enzyme inactivators. Methods Enzymol 249:240-283.
32. Simmonds AC, Reilly CA, Baldwin RM, Ghanayem BI, Lanza DL, Yost GS, Collins KS, and Forkert PG (2004) Bioactivation of 1,1-dichloroethylene to its epoxide by CYP2E1 and CYP2F enzymes. Drug Metab Dispos 32:1032-1039.
33. Skordos KW, Laycock JD, and Yost GS (1998a) Thioether adducts of a new imine reactive intermediate of the pneumotoxin 3-methylindole. Chem Res Toxicol 11:1326-1331.
34. Skordos KW, Skiles GL, Laycock JD, Lanza DL, and Yost GS (1998b) Evidence supporting the formation of 2,3-epoxy-3-methylindoline: a reactive intermediate of the pneumotoxin 3-methylindole. Chem Res Toxicol 11:741-749.
35. Sun H and Yost GS (2008) Metabolic activation of a novel 3-substituted indole-containing TNF-α inhibitor: dehydrogenation and inactivation of CYP3A4. Chem Res Toxicol, in press.
36. Thornton-Manning J, Appleton ML, Gonzalez FJ, and Yost GS (1996) Metabolism of 3-methylindole by vaccinia-expressed P450 enzymes: correlation of 3-methyleneindolenine formation and protein-binding. J Pharmacol Exp Ther 276:21-29.
37. Thornton-Manning JR, Ruangyuttikarn W, Gonzalez FJ, and Yost GS (1991) Metabolic activation of the pneumotoxin, 3-methylindole, by vaccinia-expressed cytochrome P450s. Biochem Biophys Res Commun 181:100-107.
38. Yan Z, Easterwood LM, Maher N, Torres R, Huebert N, and Yost GS (2007) Metabolism and bioactivation of 3-methylindole by human liver microsomes. Chem Res Toxicol 20:140-148.
39. Yost GS (1996) Mechanisms of cytochrome P450-mediated formation of pneumotoxic electrophiles. Adv Exp Med Biol 387:221-229.
40. Yost GS (2001) Bioactivation of toxicants by cytochrome p450-mediated dehydrogenation mechanisms. Adv Exp Med Biol 500:53-62.
41. Yost GS, Nocerini MR, Carlson JR, and Liberato DJ (1986) Structure of the adduct of glutathione and activated 3-methylindole. Adv Exp Med Biol 197:373-380.
42. 4-selective antagonist in rat, monkey, and humans: formation of a novel mercapturic acid adduct. Drug Metab Dispos 28:633-642.